Global Pain Management Therapeutics Market: Snapshot
Pain is invariably around whenever a body is suffering from diseases, which can be of multiple types including fibromyalgia, stomach ulcer, osteoarthritis, chronic arthritis, diabetic neuropathy, and cancer. Even during and after the therapy, pain constitutes a major part of the procedure that the subject has to bear but with technological advancements, it has become possible to considerably reduce the suffering and manage the pain via a variety of physiological mechanism, targeting the nociceptors for example. As the investments on robust infrastructure escalates across various emerging and developed countries, and awareness regarding the availability of alternatives increase, the demand in the global pain management therapeutics market is projected to increment at a healthy CAGR during the forecast period of 2017 to 2025.
Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1724
Currently, the developed regions of North America and Europe serve the maximum demand in the pain management therapeutics market, although highly populated emerging economies in Asia Pacific such as India and China are expected to turn into a profitable market towards the end of the forecast period.
In the current scenario, the global pain management therapeutics market is highly competitive, with the leading players constantly striving to come up with new products that are more efficient and hence gives them an edge over their competitors. In the current scenario, Purdue Pharma LP and Pfizer lead the market with nearly half the global shares, although the likes of Depomed Inc. and AstraZeneca Plc gaining ground. There is a strong presence of conventional medicines for pain management, which will keep the competitive landscape saturated throughout the forecast period. In the near future, a number of medium and small generic drugs manufacturers are expected to have a foray into pain management therapeutics market too, which will further intensity the tussle for the pole position.
Pain Management Therapeutics Market: Overview
Pain management therapeutics comprise various methods to ease varied degrees of pain among patients and improve their quality of life. Pharmaceutical therapeutics are usually the first line of treatment for pain management and if this does not work, patients opt for other methods such as pain managing devices, physiotherapy, and chiropractic therapy.
Pain management therapeutics can be categorized into antidepressants, anticonvulsants, opioids, anesthetics, antimigraine agents, non-steroidal anti-inflammatory drugs (NSAIDS), and non-narcotic analgesics. Various drugs are used for the management of different kinds of pain, such as fibromyalgia, neuropathic pain, arthritic pain, chronic back pain, post-operative pain, migraine, and cancer-related pain. A common trend that has been observed among patients is the consumption of over-the-counter (OTC) drugs rather than prescription drugs.
Pain Management Therapeutics Market: Trends
The growing prevalence of chronic diseases such as diabetes and cancer has been single-handedly driving the demand for pain management therapeutics and the number of people suffering from this kind of pain has been surging at a substantial rate. In addition to this, a massive geriatric population susceptible to arthritis, nerve damage, neuropathy, and joint pain is also boosting the market for pain management therapeutics. Supplementing market growth are favorable regulatory scenarios in many developed countries around the world.
However, as more and more patients opt for generic pain management drugs, the branded segment has been suffering a major setback. Moreover, the patent expiries of a number of blockbuster drugs will have a significant impact on the overall market for pain management therapeutics.
Pain Management Therapeutics Market: Market Potential
Despite the fact that leading brands are nearing a point of saturation, the pain management therapeutics market possesses strong potential for growth, particularly for smaller players. For instance, looking to expand its footprint in the global market as well as strengthen its U.S. pharmaceutical unit, Ireland-based Endo International plc acquired Auxilium Pharmaceuticals in 2015. The company also launched the BELBUCA Bucccal Film in 2016, which is used for the management of chronic pain.
Purdue Pharma, headquartered in Connecticut, U.S., ventured into a patent agreement with Acura Pharmaceuticals, Inc. and Egalet Corporation in 2016 for the development and sales of opioid pain management medicines.
Pain Management Therapeutics Market: Regional Outlook
Geographically, the global market for pain management therapeutics comprises North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa. North America and Europe hold the largest share in the overall market and are slated to continue their dominance throughout the forecast period. The rising consumption of advanced pain management drugs and the availability of well-established and sophisticated healthcare infrastructure are the key factors driving the North America and Europe pain management therapeutics market. Asia Pacific is an immensely lucrative region and a number of players are looking to expand their operations in the many emerging countries in the region. This can be attributed to strong economic growth in nations such as China, India, Malaysia, and Japan, rising investments in the healthcare industry in these countries, and the increasing affordability of the population.
Pain Management Therapeutics Market: Competitive Analysis
There are a host of generic as well as branded drug manufacturers in the global pain management therapeutics market. These include GlaxoSmithKline plc, Novartis AG, Johnson & Johnson, Abbott Laboratories, AstraZeneca, Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Purdue Pharma L.P., Endo Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Depomed, Inc., and Pfizer, Inc. Although companies producing branded pain management therapeutics have a strong foothold in the market, the market is actually dominated by generic drug manufacturers, giving small- and medium-scale players immense scope for growth.
Read Comprehensive Overview of Report @https://www.tmrresearch.com/pain-management-therapeutics-market
About TMR Research:
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
Read the original here:
Pain Management Therapeutics Market Worldwide Survey On Product Need 2025 - Latest Herald
- An update on Axon Therapy: A treatment used to relieve chronic neuropathy pain - Veterans Affairs - December 6th, 2024
- Hypothyroidism: Can it cause peripheral neuropathy? - December 6th, 2024
- A Case of Severe Advanced Diabetic Cardiac Autonomic Neuropathy: Severe Orthostatic Hypotension Complicated With Episodes of Nocturnal Supine... - December 6th, 2024
- Peripheral neuropathy - Care at Mayo Clinic - November 27th, 2024
- Diabetic neuropathy - Symptoms & causes - Mayo Clinic - November 27th, 2024
- Peripheral nerve injuries - Symptoms and causes - Mayo Clinic - November 27th, 2024
- Autonomic neuropathy - Symptoms & causes - Mayo Clinic - November 27th, 2024
- FDA clears IND application for epigenetic regulator to treat idiopathic neuropathy pain - Healio - November 27th, 2024
- Sponsored: Relieve Your Neuropathy with Advanced Nerve And Health Center - KHOU.com - November 27th, 2024
- Diabetic Peripheral Neuropathy Market size in the 7MM was approximately USD 2,740 million in 2022, estimated DelveInsight - The Globe and Mail - November 27th, 2024
- Peripheral neuropathy: Causes, symptoms, treatment, and prevention - September 21st, 2024
- Sponsored: Say goodbye to neuropathy with help from NexGenEsis Healthcare - KHOU.com - September 21st, 2024
- Danish Study Reveals Connection Between Diabetic Neuropathy, Retinopathy, and Severe Periodontitis - Medical Dialogues - September 21st, 2024
- What Is Neuropathy? Symptoms, Causes, Diagnosis, Treatment And ... - Forbes - July 30th, 2024
- Neuropathy | Duke Health - October 16th, 2023
- Peripheral Neuropathy | University Hospitals - May 9th, 2023
- Cranial Neuropathies | University Hospitals - May 9th, 2023
- Treatment for Peripheral Neuropathy & Other Nerve Damage | University ... - May 9th, 2023
- Neuromuscular Disease | Facts About Neuromuscular Disorders, Symptoms ... - May 9th, 2023
- Patrick McIntyre MD, JD Doctor Profile & Reviews | University Hospitals - May 9th, 2023
- Peripheral Neuropathy: What It Is, Symptoms & Treatment - Cleveland Clinic - May 1st, 2023
- Peripheral Neuropathy | National Institute of Neurological Disorders ... - May 1st, 2023
- Ionis Pharmaceuticals - Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study... - May 1st, 2023
- Successfully Treating Diabetic Neuropathy at Vero Neuropathy | Paid Content - Local 5 - weareiowa.com - May 1st, 2023
- Peripheral Neuropathy Treatment at Advanced Nerve and Health Center - WFAA.com - May 1st, 2023
- Different Types of Peripheral Neuropathy | Paid Content - Local 5 - weareiowa.com - February 24th, 2023
- Peripheral neuropathy: Symptoms, causes, and treatment - Medical News Today - February 24th, 2023
- Natural Treatments for Peripheral Neuropathy - Healthline - December 28th, 2022
- Diabetic neuropathy types: Symptoms tell the story - Mayo Clinic - December 28th, 2022
- Supplements for Neuropathy: Vitamins and More - Healthline - December 28th, 2022
- The Effectiveness of Topical Cannabidiol Oil in Symptomatic ... - PubMed - December 28th, 2022
- Autonomic neuropathy - Diagnosis and treatment - Mayo Clinic - December 28th, 2022
- Peripheral neuropathy - Causes - NHS - December 28th, 2022
- Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and ... - PubMed - December 28th, 2022
- What Is Auditory Neuropathy? Causes & Treatment | NIDCD - December 20th, 2022
- Vero Neuropathy and Their Patients Pain Free Success Stories | Paid Content - Local 5 - weareiowa.com - December 20th, 2022
- Neuropathy No More Reviews (Blue Heron Health News) Does It Work? - Outlook India - December 20th, 2022
- Neuropathy Pain Treatment Market Size to Grow by USD 3.81 Bn, Growing Focus on Emerging Economies to be a Key Trend - Technavio - Yahoo Finance - October 7th, 2022
- Pregabalin Market to Grow by USD 153.03 Mn from 2022 to 2026, Driven by Presence of Large Patient Pool Related To Neuropathic Pain - Technavio - Yahoo... - October 7th, 2022
- Anti-hyperalgesic effects of photobiomodulation therapy (904 nm) on streptozotocin-induced diabetic neuropathy imply MAPK pathway and calcium dynamics... - October 7th, 2022
- Side effects that may arise during breast cancer treatment The Hamburg Reporter - Hamburg Reporter - October 7th, 2022
- Neuropathy & the Truth About Alternative Care - North Forty News - June 16th, 2022
- Chemotherapy-Induced Peripheral Neuropathy: The Invisible Side Effect - Curetoday.com - June 16th, 2022
- Thermal gradient ring reveals thermosensory changes in diabetic peripheral neuropathy in mice | Scientific Reports - Nature.com - June 16th, 2022
- GenSight Biologics Announces Participation and Presentation of GS010 Clinical Data at EUNOS 2022 - Business Wire - June 16th, 2022
- Warning Signs of Diabetes, Says Physician Eat This Not That - Eat This, Not That - June 16th, 2022
- Foot Disease: The Most Feared Of All The Consequences Of Diabetes - Pressat - June 16th, 2022
- How Mindfulness Meditation May Help Ease Stress and Anxiety in Cancer Survivors, and Where to Start - Curetoday.com - June 16th, 2022
- TYPES OF CANNABIS STRAINS AND THE TYPE OF PAIN THEY TREAT - GISuser.com - June 16th, 2022
- 5 Types of Neuropathy and What to Do About Them | Fort ... - April 26th, 2022
- Unilateral Compressive Optic Neuropathy As the Presenting Manifestation of Clival Chordoma: A Case Report - Cureus - April 26th, 2022
- A Case of Secondary Trigeminal Neuropathy Due to Local Malignant Invasion of the Maxillary and Mandibular Nerves at the Skull Base: A Case Report With... - April 26th, 2022
- Global Leber's Hereditary Optic Neuropathy Drug Market 2022 to 2031 Analysis themobility.club - themobility.club - April 26th, 2022
- Risks of vitamin B12 deficiency and the symptoms to look out for - My London - April 26th, 2022
- NeuraLace announces two new patents for Axon neuropathic pain therapies - NeuroNews International - April 26th, 2022
- Neuropathic pain Market Overview By Share, Size, Industry Players, Revenue and Product Demand 2021-2030 The New York Irish Emgirant - The New York... - April 26th, 2022
- Find Help For Peripheral Neuropathy With Corrective Health - KXAN.com - November 21st, 2021
- AlgoTherapeutix Completes Phase I for Peripheral Neuropathy Program ATX01, Poised for Phase II Initiation in 2022 - Business Wire - November 21st, 2021
- Diabetic Neuropathy Treatment Industry Growth Forecast Analysis Manufacturers, Regions, Type and Application to 2026 - Northwest Diamond Notes - November 21st, 2021
- Diabetes: The 'tingling' sensation that can be caused by long-term high blood sugar - Daily Express - November 21st, 2021
- Vaccinations urged against shingles, a viral infection that's on the rise - Yahoo News - November 21st, 2021
- Broadway Vascular Announces Top-Line Results of 12-Month Retrospective Analysis Evaluating Revascularization of the Lateral Plantar Artery in Diabetic... - October 26th, 2021
- Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency - Yahoo Finance - October 26th, 2021
- Heres Why Alger Sold its Nevro Corp. (NVRO) Position - Yahoo Finance - October 26th, 2021
- Zika virus in UP: Symptoms, treatment and other things to know - Hindustan Times - October 26th, 2021
- Ask the GP: Why do my feet feel like they're on fire? - The Irish News - October 26th, 2021
- For veterans: VA prepares to tackle backlogged disability claims - The Herald-Times - October 26th, 2021
- Tri-State Neuropathy Centers continues to expand its peripheral neuropathy treatment practice in the tri-state area to continue its mission to help... - August 17th, 2021
- Out of Every Ten Diabetic Patient, At least Seven are Identified with Diabetic Neuropathy - BioSpace - August 17th, 2021
- CCM can identify nerve damage in patients with long COVID, new study finds - Mobihealth News - August 17th, 2021
- Spotlight on ultrasonography in the diagnosis of PND | IJGM - Dove Medical Press - August 17th, 2021
- Eye scan could determine whether COVID patients will be long haulers - WGNO New Orleans - August 17th, 2021
- Diabetic Neuropathy Treatment Market Trends and Forecast to 2027 Players are Abbott, Roche, Eli Lilly - The Manomet Current - August 17th, 2021
- The Feather and the Knife: Navigating Life With Chronic Pain - POZ - August 17th, 2021
- Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing - Yahoo Finance - August 17th, 2021
- Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update - Yahoo Finance - August 17th, 2021
- Ugly Side Effects of Too Many Vitamins - Eat This Not That - Eat This, Not That - August 17th, 2021
- Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years in the Domain - Digital... - May 14th, 2021
- Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy - BioSpace - May 14th, 2021
- Global Chronic Pain associated with Painful Diabetic Neuropathy Market to 2025 - Insight, Competitive Landscape and Forecasts - ResearchAndMarkets.com... - May 14th, 2021